Pfizer (PFE) Depreciation & Amortization (CF) (2009 - 2026)

Pfizer (PFE) has 18 years of Depreciation & Amortization (CF) data on file, last reported at $1.6 billion in Q1 2026.

• Quarterly Depreciation & Amortization (CF) changed 0.31% year-over-year to $1.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.6 billion (up 29.08% YoY) and the FY2025 annual result came in at $6.6 billion, down 6.0% from the prior year.
• Depreciation & Amortization (CF) slipped to $1.6 billion in Q1 2026 per PFE's latest filing, from $1.7 billion in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $3.5 billion in Q4 2022 and bottomed at $1.2 billion in Q3 2022.
• The 5-year median for Depreciation & Amortization (CF) is $1.6 billion (2025), against an average of $1.7 billion.
• Peak annual rise in Depreciation & Amortization (CF) reached 33.87% in 2023, while the deepest fall reached 55.99% in 2023.
• Tracing PFE's Depreciation & Amortization (CF) over 5 years: stood at $3.5 billion in 2022, then tumbled by 52.89% to $1.7 billion in 2023, then climbed by 5.09% to $1.8 billion in 2024, then slipped by 3.87% to $1.7 billion in 2025, then declined by 4.39% to $1.6 billion in 2026.
• Per Business Quant, the three latest PFE Depreciation & Amortization (CF) figures stand at $1.6 billion (Q1 2026), $1.7 billion (Q4 2025), and $1.7 billion (Q3 2025).

Peer Comparison